141676-35-9
141676-35-9 结构式
基本信息
H-Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH
GLY-LEU-SER-LYS-GLY-CYS-PHE-GLY-LEU-LYS-LEU-ASP-ARG-ILE-GLY-SER-MET-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG-TYR ((DISULFIDE BRIDGE: CYS6-CYS22)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2023/03/20 | HY-P1556 | Vasonatrin Peptide (VNP)
Vasonatrin Peptide (VNP) | 141676-35-9 | 500μg | 2000元 |
| 2023/03/20 | HY-P1556 | Vasonatrin Peptide (VNP)
Vasonatrin Peptide (VNP) | 141676-35-9 | 1mg | 3600元 |
| 2023/03/20 | HY-P1556 | Vasonatrin Peptide (VNP)
Vasonatrin Peptide (VNP) | 141676-35-9 | 5mg | 9900元 |
常见问题列表
Natriuretic peptide receptors
Vasonatrin peptide binds with both natriuretic peptide receptor A and B, but with a preference for B. VNP-stimulated cGMP is 11-fold greater in NPRB than NPRA.
The high-fat diet-fed streptozotocin-induced diabetic Sprague-Dawley rats are subjected to ischemia-reperfusion operation. VNP treatment (100 g/kg iv, 10 min before reperfusion) significantly improved the instantaneous first derivation of left ventricle pressure (LV dP/dtmax) and LV systolic pressure and reduced LV end-diastolic pressure, apoptosis index, caspase-3 activity, plasma creatine kinase (CK), and lactate dehydrogenase (LDH) activities. Treatment hypoxia-induced pulmonary hypertension (HPH) with Vasonatrin peptide for 1 week significantly reduceS mean pulmonary arterial pressure, pulmonary vascular resistance, RVH and muscularization of the pulmonary arteries. Acute intravenous administration of 50 microg/kg Vasonatrin peptide significantly ameliorates pulmonary haemodynamics in HPH rats.